Literature DB >> 27895163

G-Protein-Coupled Receptor Kinase 2 as a Potential Modulator of the Hallmarks of Cancer.

Laura Nogués1, Clara Reglero1, Verónica Rivas1, María Neves1, Petronila Penela1, Federico Mayor2.   

Abstract

Malignant features-such as sustained proliferation, refractoriness to growth suppressors, resistance to cell death or aberrant motility, and metastasis-can be triggered by a variety of mutations and signaling adaptations. Signaling nodes can act as cancer-associated factors by cooperating with oncogene-governed pathways or participating in compensatory transduction networks to strengthen tumor properties. G-protein-coupled receptor kinase 2 (GRK2) is arising as one of such nodes. Via its complex network of connections with other cellular proteins, GRK2 contributes to the modulation of basic cellular functions-such as cell proliferation, survival, or motility-and is involved in metabolic homeostasis, inflammation, or angiogenic processes. Moreover, altered GRK2 levels are starting to be reported in different tumoral contexts and shown to promote breast tumorigenesis or to trigger the tumoral angiogenic switch. The ability to modulate several of the hallmarks of cancer puts forward GRK2 as an oncomodifier, able to modulate carcinogenesis in a cell-type specific way.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27895163     DOI: 10.1124/mol.116.107185

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

1.  G protein-coupled receptor kinases: Past, present and future.

Authors:  Konstantin E Komolov; Jeffrey L Benovic
Journal:  Cell Signal       Date:  2017-07-12       Impact factor: 4.315

Review 2.  The role of G protein-coupled receptor kinases in the pathology of malignant tumors.

Authors:  Wu-Yi Sun; Jing-Jing Wu; Wen-Ting Peng; Jia-Chang Sun; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2018-06-19       Impact factor: 6.150

3.  GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein.

Authors:  Jing Cheng; Linda R Klei; Nathaniel E Hubel; Ming Zhang; Rebekka Schairer; Lisa M Maurer; Hanna B Klei; Heejae Kang; Vincent J Concel; Phillip C Delekta; Eric V Dang; Michelle A Mintz; Mathijs Baens; Jason G Cyster; Narayanan Parameswaran; Margot Thome; Peter C Lucas; Linda M McAllister-Lucas
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

Review 4.  Differential Regulation of GPCRs-Are GRK Expression Levels the Key?

Authors:  Edda S F Matthees; Raphael S Haider; Carsten Hoffmann; Julia Drube
Journal:  Front Cell Dev Biol       Date:  2021-05-24

5.  GRK2 promotes growth of medulloblastoma cells and protects them from chemotherapy-induced apoptosis.

Authors:  Anup S Pathania; Xiuhai Ren; Min Y Mahdi; Gregory M Shackleford; Anat Erdreich-Epstein
Journal:  Sci Rep       Date:  2019-09-25       Impact factor: 4.996

Review 6.  G Protein-Coupled Receptor Kinase 2 (GRK2) as a Potential Therapeutic Target in Cardiovascular and Metabolic Diseases.

Authors:  Cristina Murga; Alba C Arcones; Marta Cruces-Sande; Ana M Briones; Mercedes Salaices; Federico Mayor
Journal:  Front Pharmacol       Date:  2019-02-19       Impact factor: 5.810

Review 7.  G protein-coupled receptor kinase 2 (GRK2) as a multifunctional signaling hub.

Authors:  Petronila Penela; Catalina Ribas; Francisco Sánchez-Madrid; Federico Mayor
Journal:  Cell Mol Life Sci       Date:  2019-08-20       Impact factor: 9.261

8.  The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review.

Authors:  Hadrien Golay; Simona Jurkovic Mlakar; Vid Mlakar; Tiago Nava; Marc Ansari
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

Review 9.  New Routes in GPCR/β-Arrestin-Driven Signaling in Cancer Progression and Metastasis.

Authors:  Anna Bagnato; Laura Rosanò
Journal:  Front Pharmacol       Date:  2019-02-19       Impact factor: 5.810

10.  GRK2 enforces androgen receptor dependence in the prostate and prostate tumors.

Authors:  Adam J Adler; Payal Mittal; Adam T Hagymasi; Antoine Menoret; Chen Shen; Federica Agliano; Kyle T Wright; James J Grady; Chia-Ling Kuo; Enrique Ballesteros; Kevin P Claffey; Anthony T Vella
Journal:  Oncogene       Date:  2020-01-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.